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Abstract
Head and neck squamous cell carcinoma (HNSCC) accounts for a bulk of the oral and laryngeal cancers, the majority
(70%) of which are associated with smoking and excessive drinking, major known risk factors for the development
of HNSCC. In contrast to reports that suggest an inverse relationship between smoking and global DNA CpG methyl-
ation, hypermethylation of promoters of a number of geneswas detected in saliva collected frompatients with HNSCC.
Using a sensitivemethylation-specific polymerase chain reaction (MSP) assay to determine specificmethylation events
in the promoters of RASSF1A, DAPK1, and p16 genes, we demonstrate that we can detect tumor presence with an
overall accuracy of 81% in the DNA isolated from saliva of patients with HNSCC (n = 143) when compared with the
DNA isolated from the saliva of healthy nonsmoker controls (n= 31). The specificity for this MSP panel was 87% and
the sensitivity was 80% (with a Fisher exact test P< .0001). In addition, the test panel performed extremely well in the
detection of the early stages of HNSCCs, with a sensitivity of 94% and a specificity of 87%, and a high κ concordance
value of 0.8, indicating an excellent overall agreement between the presence of HNSCC and a positive MSP panel
result. In conclusion, we demonstrate that the promoter methylation of RASSF1A,DAPK1, and p16MSP panel is useful
in detecting hypermethylation events in a noninvasive manner in patients with HNSCC.
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Introduction
There are 780,000 new cases of head and neck squamous cell carci-
noma (HNSCC) worldwide each year, which result in more than
300,000 deaths annually. HNSCC is often associated with a poor
prognosis and has a significant impact on morbidity, mortality,
and health-care expenditure. Squamous cell carcinomas, in particular
their oral form, represents a significant proportion of HNSCC, and
accounts for 90% of all tumors with a relatively low 5-year survival
rate [1]. This poor prognosis is largely caused by the late diagnosis
of the disease [1]. About 30% to 50% of HNSCC are caused as a
direct result of human papilloma viral infections [2]. The absence of
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definitive early warning signs for oral HNSCCs highlights the need
for sensitive and specific biomarkers that would have a clear utility
and be of significant importance for screening, particularly in high-
risk individuals [3]. Detection of HNSCC is currently based on an
expert clinical examination of the upper aerodigestive tract and histo-
logic analysis of suspicious areas, but lesions can remain undetected in
obscured sites such as the crypts at the base of the tongue and tonsils.
It is therefore imperative to develop tools to diagnose HNSCC at an
early stage of the disease enabling effective and timely interventions
whereby reducing mortality and morbidity associated with this type
of cancer.
Tobacco use is a major risk factor for HNSCC and smoking kills
more than 1,000,000 people a year worldwide, accounting for 30%
of all cancer-related deaths. According to the World Health Organi-
zation report [4], one in three people worldwide is addicted to nico-
tine. Smoking is thought to be responsible for ∼45% of HNSCC
cases in men and 75% of cases in women [5]. Smoking has been
associated with significant changes in the methylation status of the
genome, causing hypomethylation and potential destabilization of
many repetitive, including retro-transposon–derived, sequences.
Smoking can, however, also promote hypermethylation of CpG
islands within promoters of tumor-suppressor genes, thus repressing
their expression [6,7], and this is a well-recognized early epigenetic
event in cancer [8,9]. Several genes are frequently methylated in
HNSCCs, such as the cell cycle regulator p16INK4a, DAPK1, and
RASSF1A, all three of which are known to act as modulators of
apoptosis [10,11].
Human saliva is an ideal diagnostic medium for investigating
smoking-related cancers because of the close proximity between the
oral cavity and the sites of occurrence of the relevant types of
HNSCC. Saliva further represents an extremely attractive diagnostic
biologic fluid, in particular for DNA-based diagnostics, because of
both the ease of collection in a clinical setting [12] and its slightly
basic nature (in general, a healthy human saliva has a pH of 7.4)
[13] that appears to facilitate the preservation of intact high molec-
ular weight DNA [14–16]. Indeed, saliva represents a unique bio-
logic fluid that may offer a diagnostic window on the status of the
whole organism as it carries a compendium of biomarkers derived
from a wide range of organs and systems [17]. It is important to
discern a sampling method that will be least affected by the disease
status and, more importantly, will enable sensitive detection of the
potential malignant transformation at a particular site. Our study
objectives were three-fold: first, to compare two saliva collection
methods, which provide distinct ways of sampling within the oral
cavity [drool method yielding mainly unstimulated saliva [7] vs the
oral scrapes using DNA-SAL (Oasis Diagnostics Corporation)],
as there are many other methods of saliva collection, including
swabs, spitting, etc., that were not used in this study (Mohamed
et al., accepted to the Journal of Clinical and Translational Medi-
cine, August, 2012); second, to determine whether DNA methylation
of CpG islands in the promoters of RASSF1A, DAPK1, and p16INK4a
in saliva-derived DNA is a surrogate noninvasive biomarker panel to
discriminate healthy controls from patients with HNSCC; and third,
to investigate whether the methylation status of CpG islands in the
three target promoter genes in the DNA isolated from saliva collected
from healthy control nonsmokers versus smokers can potentially serve
as noninvasive screening method for early detection of HNSCC. Our
study highlights the utility of saliva for methylation-specific poly-
merase chain reaction (MSP)–based diagnostic detection of smoking-
associated DNA promoter hypermethylation of DAPK1, RASSF1A,
and p16INK4a during various stages of the HNSCC development and
progression. We have therefore demonstrated that saliva can be used
as an analytical matrix for the development of a noninvasive and
cost-effective MSP-based test, which allows for the early detection of
promoter hypermethylation associated with gene cellular transformation
events in patients with HNSCC.
Materials and Methods
Study Design
This study was approved by the University of Queensland Medical
Ethical Institutional Board and by the Princess Alexandra Hospital
Ethics Review Board. All participants gave informed consent before
sample collection. Healthy control subjects (n = 46 both smokers
and nonsmokers, n = 31 healthy nonsmokers) without any clinical signs
of cancer as well as patients with HNSCC (n = 143) at various clinical
stages of cancer (stages I–IV) were recruited to our study (Table 1).
Saliva Sample Collection
DNA promoter methylation of the three-gene panel was assayed in
DNA isolated from whole mouth saliva (drool, unstimulated) and
from buccal cell scrape samples (DNA-SAL) from both patients with
HNSCC and healthy controls, both smokers (including recent quitters)
and nonsmokers. The volunteers were asked to sit in a comfortable
upright position and were asked to rinse their mouth with water (to
remove food debris) and were asked to tilt their heads down and to pool
saliva in the mouth for about 2 to 5 minutes. Saliva samples were
collected in sterile urine containers (Sarstedt, Australia) and were trans-
ported on dry ice to the laboratory. Samples were then thawed at room
temperature and centrifuged at 500g at 4°C for 10 minutes. The super-
natant was discarded and the cellular pellet was frozen at −80°C until
further analysis. Collection of buccal cell scrapings was performed using
DNA-SAL Salivary DNA Collection Device (Oasis Diagnostics Cor-
poration) as per the manufacturer’s protocol with the exception that
TE buffer was used in place of the stabilization buffer provided by
the manufacturer. Cell scrapes were rinsed with TE buffer and were
centrifuged (500g at 4°C) to collect the cell pellets and these were stored
at −80°C.
DNA Extraction and Bisulfite Conversion of Saliva Samples
DNA extraction and subsequent bisulfite conversions were carried
out using the EpiTect Plus Kit (Qiagen, Valencia, CA) according to
the manufacturer’s instructions with the exception of a longer incu-
bation time (10 minutes instead of 1 minute) and the use of a larger
elution volume (17 μl instead of 15 μl). Bisulfite-converted DNA was
eluted from the column in elution buffer (10 mMTris-HCl, pH 8.0) and
immediately used for the first-stage nested MSP or stored at −80°C. All
Table 1. Demographic Characteristics of Study Participants.
Healthy Controls Patients with HNSCC P
Age (mean ± SD) 48 ± 9 62 ± 13 <.0001
Gender
Females 21 (46%) 31 (22%) .012
Males 25 (54%) 112 (78%)
Smoking status
Smokers 15 (33%) 119 (83%) >.001
Nonsmokers 31 (67%) 24 (20%) κ = 0.3
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the converted DNA samples were assessed for their DNA purity and
quantified on a ND-1000 Spectrophotometer (Thermo Scientific,
Wilmington, DE).
Nested MSP Analysis of the Biomarker Panel
The selection of the three-gene panel (RASSF1A, p16INK4a, and
DAPK1) was based on existing data showing high concordance be-
tween hypermethylation of the promoters of these genes and oral
cancers [18,19]. MSP is the most commonly used method for detect-
ing methylated or unmethylated alleles in human genomic DNA [10].
In this study, we used a modification of a previously reported ap-
proach [6] to detect methylation at specific sites located at (or near)
the 3′ ends of the genes [20] of RASSF1A, p16INK4a, and DAPK1 (see
Table 2 and Figure 1A). Briefly, first-stage methylation-independent
primers were used at 0.5 μM in a standard polymerase chain reaction
(PCR) (25 μl of reaction volume), using Taq DNA polymerase (TDP-
500 Scientifix) with 2 to 5 μl of converted DNA template (diluted
either three or five times depending on the DNA concentration) with
supplied buffers/dNTPs using the following cycling conditions:
30 cycles of 15 seconds at 94°C, 15 seconds at 60°C, and 15 seconds
at 72°C. To detect unmethylated or methylated alleles for DAPK1,
separate second-stage reactions were carried out using similar cycling
conditions and the corresponding primer set. For RASSF1A and
p16INK4a, second-stage unmethylated and methylated PCRs were
touchdown gradient PCRs, with annealing temperature decreasing
from 64°C to 58°C in 2°/5-cycle steps. PCR products were visualized
on 2% agarose gel electrophoresis in 1× TAE buffer. As a positive con-
trol for methylation-specific PCR, we used bisulfite-converted meth-
ylated HeLa cell line (NEB, Ipswich, MA, Catalogue No. 4007s).
Only MSP primer sets amplifying methylated alleles not present in
the majority of normal cellular DNA as well as transformed cell lines
of unrelated etiologies were selected for these assays. Thus, the results
of the nested MSP reactions were interpreted in a binary manner,
such that presence of any detectable amplification product using a
methylated allele-specific primer set was interpreted as a positive re-
sult. Each reaction of the first round of nested MSPs was carried out
with one of the three gene-specific primer pairs. As an internal control
for the quality of each bisulfite-converted gDNA sample, a second
round of unmethylated allele-specific MSPs was carried out for all
the three genes. Only samples that gave a strong consistent band using
the unmethylated allele-specific reference PCR were used for promoter
methylation analysis of RASSF1A, p16INK4a, and DAPK1.
Statistical Analysis of the Results
Determination of the clinical performance (sensitivity, specificity,
and accuracy, as well as positive and negative predictive values) was
performed using standard algorithms based on the 2 × 2 contingency
tables (specific for each comparison) and using an available online
resource hosted by the Johns Hopkins Medical Center (http://www.
rad.jhmi.edu/jeng/javarad/roc/JROCFITi.html). Standard error and
confidence intervals (CIs) for sensitivity and specificity were calculated
using standard formulas and a multiplier of 1.96 for 95% CI [21].
Fisher exact test and other parameters used for data evaluation were also
calculated using online statistical resources (e.g., http://statpages.org/
ctab2x2.html). Agreement quality (κ) quantification using the same
2 × 2 contingency tables was performed using the GraphPad online
resource (http://graphpad.com/quickcalcs/kappa1.cfm).
Results
Validation of the Performance of the Three-Marker Panel in
Diagnosing HNSCC
Of a cohort of 143 patients with HNSCC, only 24 had never
smoked according to the World Health Organization criteria (http://
www.who.int/whosis/indicators/compendium/2008/2ptu/en/index.
html). The analysis of DNA methylation at the three promoters of
DAPK1, p16INK4a, and RASSF1A genes in the saliva collected either
as a drool sample or with the use of a DNA cell scrape allowed us to
identify individuals with HNSCC with an overall accuracy of 81%
(P = .05, CI = 75–84%) in patients with HNSCC when compared
with healthy nonsmoker controls (n = 31). The test also yielded high
specificity of 87% (71–96%) and sensitivity of 82% (78–84%) for the
three-marker panel, with a Fisher exact test (P < .0001). The test is also
characterized by a very high positive predictive value (0.97, P = .05,
CI = 0.93–0.99) and a good negative predictive value (NPV) (0.5).
As expected, the overall positiveness for the panel appeared to correlate
well with the presence of the HNSCC, with κ = 0.51.
The test panel performed particularly well in the detection of early
stage HNSCCs, with detection of well to poorly differentiated SCCs
(grade II) with a high sensitivity of 94% (P = .05, CI = 85–98), a
specificity of 87%, an accuracy of 91%( P = .05, CI = 81–96%), and a
very high concordance between positiveness for the MSP panel and the
presence of the tumor(s), with κ value of 0.8, indicating a fair overall
agreement. For patients with grade III tumors, a similar specificity of
87% was observed, with an overall accuracy of 86%. The test also per-
formed well in the detection of the metastatic HNSCC (grade IV), at
an accuracy of 87%, a sensitivity of 88%, and a specificity of 87%, with
P < .001. Determination of the κ value (0.72) indicated a good agree-
ment between gene promoter hypermethylation and the overall inci-
dence of HNSCC, with κ at 0.8 for grade II and good agreement at
κ = 0.7 for grade III (see also Figure 2). Similarly, the NPV rose from
0.53 for grade I/II to 0.60 for grade III and 0.72 for grade IV. It is clear
from Figure 1, depicting a fraction of samples in categories that tested
positive for the marker set and that the panel as a whole acts as a better
Table 2. The MSP Primers Used in Our Study.
Gene Nucleotide Sequence PCR Product
Size (bp)
Primer sequences for stage 1 PCR (methylation-independent)
p16 Forward: 5′-GAGGAAGAAAGAGGAGGGGTTG-3′ 274
Reverse: 5′-ACAAACCCTCTACCCACCTAAATC-3′
RASSF1A Forward: 5′-GGAGGGAAGGAAGGGTAAGG-3′ 260
Reverse: 5′-CAACTCAATAAACTCAAACTCCC-3′
DAPK1 Forward: 5′-GGTTGTTTYGGAGTGTGAGGAGG-3′ 236
Reverse: 5′-CTAAAAACTCCCCCRATCCCT-3′
Stage 2 primer sequences—unmethylated allele-specific
p16 Forward: 5′-TTATTAGAGGGTGGGGTGGATTGT-3′ 145
Reverse: 5′-CAACCCCAAACCACAACCATAA-3′
RASSF1A Forward: 5′-GGTTTTGTGAGAGTGTGTTTAG-3′ 172
Reverse: 5′-ACACTAACAAACACAAACCAAAC-3′
DAPK1 Forward: 5′-GGAGGATAGTTGGATTGAGTTAATGTTT-3′ 80
Reverse: 5′-CAAATCCCTCCCAAACACCAA-3′
Stage 2 primer sequences—methylated allele-specific
p16 Forward: 5′-GAGGGTGGGGCGGATCGC-3′ 143
Reverse: 5′-GACCCCGAACCGCGACCG-3′
RASSF1A Forward: 5′-GGGGGTTTTGCGAGAGCGC-3′ 203
Reverse: 5′-CCCGATTAAACCCGTACTTCG-3′
DAPK1 Forward: 5′-ATAGTCGGATCGAGTTAACGTC-3′ 152
Reverse 5′-AAAACTAACCGAAACGACGACG-3′
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indicator of HNSCC status than when a single gene (p16) is used in
a stand-alone fashion (Figure 1B).
Comparison of DNA Methylation of the Three Target Genes in
Saliva Collected Using the Drool Method versus DNA-SAL
To perform a comparative evaluation of the drool and DNA-SAL
collection methods, we used both sampling methods to obtain
bisulfite-converted DNA samples from 53 patients with HNSCC.
After the quality of all 106 (53 × 2) samples was confirmed using
MSP primer sets specific for unmethylated variants of the gene panels’
promoters, detection of the hypermethylated variants using the three-
gene panel was carried out. Twelve patients were negative in the
drool- and the DNA-SAL–derived DNA samples. In 19 cases, posi-
tive results were obtained from both the drool and DNA-SAL sam-
ples. Fourteen cases were positive in the drool-derived DNA samples
only, and the remaining eight cases were positive in DNA-SAL– but
not saliva-derived samples. Estimation of the κ value suggests not only
a lack of statistically significant agreement (i.e., that measurements are
indeed likely to survey correlating parameters) but also the fact that
with high likelihood the measurements from the two tests are totally
unrelated, as could be expected because of an essentially distinct
nature of sampled cellular populations (see further discussion below),
with the predicted value of κ < −0.3.
Effects of Smoking on DNA Hypermethylation within the
Control Group
When comparing the smoker healthy controls with nonsmoker
healthy controls, the methylation of the three-marker panel corre-
lated moderately well with the smoking status (for DAPK1 and
p16INK4a, with an accuracy of 72%, a specificity of 87%, and a con-
cordance coefficient of ∼0.3). In contrast, when these markers were
individually tested, they gave a better agreement with smoking status.
For instance, in the patient group,DAPK1 was predictive for the smok-
ing status with a high degree of specificity (88%, high positive predic-
tive value). A high specificity of 84% was also observed for p16INK4a.
Discussion
Our study clearly demonstrates the clinical utility of using saliva as a
biologic matrix to detect the molecular changes that occur in a tumor
sample. DNA methylation of DAPK1, p16INK4a, and RASSF1A can
be used to predict the risk of incidence of HNSCC in individuals,
highlighting the potential as a screening biomarker panel in high-risk
Figure 1. (A) The detection of the promoter hypermethylation events for p16 across different sample groups and tumor grades. U =
unmethylated PCR and M = methylated MSPs; samples 1 to 4 are four different patient samples, samples 5 and 6 are HeLa positives,
and sample 7 is a negative PCR control. (B) The percentages of samples positive for either whole three-gene MSP panel (dark gray) or
p16 (light gray columns) in different categories.
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groups. In addition, the test panel performed very well (specificity
of 87% and sensitivity of 80%) in the detection of early stage
HNSCCs, with detection of well to poorly differentiated HNSCCs
further illustrating the screening power of this DNA methylation
marker panel. DNA promoter hypermethylation of DAPK1 and
p16INK4a was significantly associated with smoking status. Our data
are consistent with recent animal and in vitro work, demonstrating
that the prevalence of p16INK4a methylation increases with the dura-
tion of smoking in a dose-dependent fashion [22–24]. In addition,
methylation of p16INK4a was significantly associated with the pack
years smoked [25]. Tobacco smoke has been shown to affect the
methylation of the DAPK1 and p16INK4a promoters, although the
precise mechanism still remains to be elucidated.
Saliva composition can constitute a representative “sampling
matrix” for many molecular and physiological processes in the human
body and can therefore be an extremely useful medium for detecting
unwanted changes in many organ systems. At the same time, when
the highest sensitivity is sought, it is more advantageous to analyze
tissue at a specific locale as provided by the DNA-SAL tool. This latter
method provides a scrape from the selected locale on the inner cheek
and also has the advantage of providing larger amounts of the cellular
material. The drawbacks of this method include its slightly more in-
vasive nature and potentially the fact that in these particular patients
scrapings are normally taken from outside of the area of the lesion,
resulting in an increase in the noise from the normal buccal tissue
and a dilution of signal from HNSCC cells. Saliva also contains cel-
lular populations of mobilized cells that are likely to be enriched with
tumor-derived cells (from our own observations, the abundance of the
cellular component of saliva strongly and positively correlated with
severity of oral HNSCC lesions), incidentally including those from
tumors outside of the oral cavity, which could still be of significant
relevance for diagnostic purposes.
One of the many factors contributing to the poor 5-year survival
rate for HNSCCs is the delay in tumor diagnosis. To ameliorate this,
a simple, noninvasive, and economical test would provide an ideal
screening tool for use with large cohorts of high-risk groups. Saliva
collection by the unstimulated drool method is possibly the most
noninvasive test available for harvesting bodily fluids, with the excep-
tion perhaps of urine collection. The work by Esteller et al. has dem-
onstrated aberrant DNA promoter methylation in the sputum samples
of patients with lung cancer up to 3 years before the clinical manifesta-
tion of the disease [26]. Similarly, they were able to identify patients at
high risk of developing lung cancer by detecting DNA hypermethylation
in sputum samples in a prospective study. We have demonstrated
that DNA methylation of DAPK1, p16INK4a, and RASSF1A in saliva
provides a highly sensitive method for the detection of promoter
hypermethylation not only in patients with HNSCC but also in dis-
criminating healthy smokers from nonsmokers with a high specificity of
73%, suggesting likely causative correlation between monitored hyper-
methylation events and smoking.
The panel of genes we used for the MSP is fairly compact and con-
sists only of three elements. This simplicity together with the relative
low cost of MSP analysis renders the assay amenable to point-of-care
test development. The qualitative nature of the MSP assays used in
our study, in conjunction with significant advances in the devel-
opment of small-scale DNA analytical devices (such as molecular
beacons), is likely to lead to the future development of highly portable
detection devices. It is also important to note the high specificity of
the MSP test for the hypermethylation of the promoters of the tumor-
suppressor genes in individuals who smoke, suggesting the possibility
of use of similar testing protocols as an “early warning” of molecular
changes in cells in the oral cavity of smokers. It is also important to
highlight the significance of the higher sensitivity of salivary DNA
MSP testing compared to the buccal cell scrape, it is likely to be be-
cause of a higher contribution by the normal buccal cellular material,
and it is likely to be augmented by the wider representation of cells
from various locales (and possibly shed more motile tumor cells) in
the saliva.
Our study investigates three genes with high relevance to neo-
plastic transformation, which have been previously reported to be
Figure 2. Detection of the promoter hypermethylation using MSPs and in patients with different tumor grades. (A) Sensitivity and spec-
ificity (expressed as percentages) for each of the MSP markers used singly and in the three-gene panel combination. Notably, DAPK1
hypermethylation detection is very highly specific but found only in a small fraction of patients (see text for more details). Sample sizes
were 31 for controls and 143 for patients with HNSCC. (B) Grade-specific breakdown of the detection of hypermethylation in patient
saliva samples using the three-gene panel. Notice that detection sensitivity increases with the advancement of the tumor stage. In A and
C bars, P = .05 CIs.
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hypermethylated in HNSCC saliva [2]. Interestingly, the percentage
of positive samples in our study appears significantly higher for the
RASSF1A gene (∼50% vs 17% reported by Righini et al. [18]) and
very similar for the other two genes, p16 and DAPK1, at around 25%
and 15%, respectively [2]. This is possibly because of the fact that
Righini et al. surveyed methylation at a different CpG site(s) using
RASSF1A MSP when compared with our study, in which we probed
the site that appears to be more frequently methylated in HNSCC
and thus a significantly more sensitive readout in detection of the
potentially undesirable hypermethylation of RASSF1A. The increase
in frequency of methylation events detected using our panel correlates
well with the tumor’s histologic grade (Figure 2B), suggesting disease
relevance of the assessed hypermethylation sites within the panel of
selected genes.
In summary, using patients with HNSCC and healthy control
samples, we demonstrate the relevance of a compact three-gene panel
MSP-based screening tool for the identification of HNSCC and
associated hypermethylation events in saliva. We also illustrate the
suitability of the saliva test for assessing the hypermethylation of
tumor-suppressor genes and demonstrate that a subset of the CpG
islands in the RASSF1A promoter represents a better target for poten-
tial risk prediction tests.
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